{"filings":[{"id":722796,"accession_number":"0001493152-26-025629","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-05-28T20:30:30+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on May 21, 2026 for failing to timely file Q1 2026 Form 10-Q under Listing Rule 5250(c)(1).","No immediate effect on listing or trading of common stock (CDT) or warrants (CDTTW).","Must submit a plan to regain compliance by July 20, 2026.","Company anticipates filing Form 10-Q shortly upon completion of the current draft review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-05-28","daily_digest_url":"/daily/2026-05-28","daily_digest_rank":7},{"id":470359,"accession_number":"0001493152-26-023707","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-05-15T20:01:42+00:00","items":["1.01","9.01"],"status":"ready","headline":"CDT Equity amends ELOC and convertible note; retains 90% of future proceeds, sets $510K purchase cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 2 caps regular ELOC purchase at $510,000 without purchaser consent; extends adjustment period until all shares sold.","Note Amendment allows CDT to retain 90% of proceeds from future financings; only 10% goes toward the convertible note.","Both amendments expire May 31, 2026, applying only to May 2026 transactions.","Amendments were with institutional investor Ascent Partners Fund LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96618,"accession_number":"0001493152-26-019133","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CDT Equity appoints Ulrik Olsen to board; Freda Lewis-Hall resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Freda Lewis-Hall resigned from board on April 27, 2026 for family health reasons; no disagreement with company.","Ulrik Olsen appointed as director and member of Audit, Compensation, and Nominating Committees.","Chele Chiavacci Farley named board chair and Nominating Committee chair; Simon Fry appointed Audit Committee chair.","Olsen, age 50, is a NZ-based property executive and holds ~7.84% ownership in Sarborg Ltd., a company in which CDT holds 20% equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110670,"accession_number":"0001493152-26-012538","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"CDT Equity Inc. announces 1-for-25 reverse stock split effective March 26, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:25 ratio; effective March 26, 2026 at 5:00 pm ET.","Common stock to trade split-adjusted under ticker CDT from March 27, 2026.","Outstanding shares reduced to approximately 4,722,450; no fractional shares issued.","Par value unchanged at $0.0001; equity awards and warrants proportionally adjusted.","Stockholders need not take action; positions adjusted automatically by brokers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110669,"accession_number":"0001493152-26-011270","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CDT Equity stockholders approve redomestication to Cayman Islands, reverse stock split, and share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redomestication from Delaware to Cayman Islands approved (Proposal 6): ~2.22M for, 72K against, 21.9K abstain.","Authorized common shares increased from 250M to 500M (Proposal 5): ~2.23M for, 77K against.","Reverse stock split authorized (Proposal 4) at ratios 1:2 to 1:100 (aggregate 1:250) at board discretion.","Issuance of up to 109.98M shares upon exercise of pre-funded warrants (Proposal 3) and 3.69M shares (Proposal 1) approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110668,"accession_number":"0001493152-26-009367","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CDT Equity lowers ELOC floor to $0.60 and issues $555K convertible note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment cuts ELOC floor price to $0.60; max shares issuable ~41.7M, subject to stockholder approval.","Issued Senior Secured Convertible Promissory Note for up to $555,556 principal at 10% interest, matures July 3, 2026.","Note convertible at Nasdaq closing price on stockholder approval date; secured by assets and guaranteed.","Company must hold stockholders' meeting by May 3, 2026 to approve conversion shares.","Note may be prepaid on 10 days' notice; mandatory prepayment upon equity offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110667,"accession_number":"0001493152-26-007906","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CDT Equity acquires 20% of Sarborg for stock, warrants, deferred $8M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 1,020 Sarborg shares (~20% stake) in exchange for 598,006 shares + pre-funded warrants for 109,978,918 shares at $0.0001 exercise price.","Agreed to pay Sarborg $8M cash, deferred until CDT raises ≥$20M via ATM program.","Issued 199,734 shares to NJS Foresight ($150k retainer) and 341,702 shares to Thesprogen ($245k retainer) for consulting extensions.","Issued 130,000 unregistered shares to Maxim Partners for investment banking services.","Directors Andrew Regan and Chele Farley have ties to Sarborg; Farley received 10,533 shares + 1,940,804 warrant shares in the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110666,"accession_number":"0001493152-26-003244","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CDT Equity enters $25M equity line of credit with Ascent Partners; issues 204,031 commitment shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CDT Equity entered a directed stock purchase agreement for up to $25M of common stock with institutional investor Ascent Partners.","Company may draw up to $750K per regular closing or $5M per expanded closing, subject to volume and price conditions.","Initial floor price of $1.35; pricing at 97%/95%/94% of VWAP based on stock price tiers.","As commitment, CDT will issue 204,031 shares to Ascent Partners; registration rights agreement filed to register resale.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110665,"accession_number":"0001493152-26-000143","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CDT enters consulting pacts with Thesprogen and NJS; issues 213,288 shares for $305k in services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thesprogen will evaluate AZD1656 pre-clinical data and optimize development strategies; 6-month term, $155k fee paid in 108,392 shares.","NJS to identify out-licensing partners for solid-form patent portfolio; $150k retainer in 104,896 shares plus 8% commission on transactions.","Shares issued in unregistered transaction under Regulation D; no registration rights granted.","Press release highlights NJS engagement to accelerate licensing and royalty-based deals for solid-form assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127292,"accession_number":"0001493152-25-027489","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CDT sells CPL subsidiary to CEO affiliate Corvus for $7M to offload Strand litigation liability","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CDT sells CPL to Corvus Capital (wholly-owned by CEO Andrew Regan) for $7M in common stock or pre-funded warrants.","Settlement of 3,910,615 shares at $1.79; beneficial ownership capped at 19.99%, warrants subject to shareholder approval up to 49.99%.","Corvus indemnifies CDT for any adverse judgment in Strand Hanson litigation (trial concluded Oct 28, 2025).","If CPL wins cost recovery, Corvus pays CDT the lesser of $1M or recovered costs.","CDT to file resale registration statement within 60 days for the issued shares/warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127291,"accession_number":"0001493152-25-017533","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"CDT Equity announces 1-for-8 reverse stock split effective October 10, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split of every 8 shares into 1, effective Oct 10, 2025 at 5:00 PM ET.","Common stock will begin trading on split-adjusted basis Oct 13 under symbol CDT, new CUSIP 20678X403.","Outstanding shares reduced to approximately 1,352,448; par value remains $0.0001.","No fractional shares issued; fractional holders receive cash based on closing price on effective date.","Stockholders approved reverse split authority on May 5, 2025; board set ratio at 1-for-8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144082,"accession_number":"0001641172-25-023840","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"CDT Equity restates Q1 2025 financials; $0.4M milestone misclassified as R&D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Aug 8, 2025, CDT Equity determined its unaudited Q1 2025 financials should no longer be relied upon.","$0.4 million in milestone payments to Sarborg Limited were misclassified as R&D expense instead of an acquired diagnostic asset.","The restatement requires amendments to the Q1 2025 10-Q, affecting balance sheet, income statement, and cash flows.","The Audit Committee and independent accounting firm CBIZ CPAs agreed on the restatement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144081,"accession_number":"0001641172-25-022760","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.02","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Conduit renames to CDT Equity Inc., appoints James Bligh permanent CFO, adds 2M shares to incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.","James Bligh, co-founder and interim CFO since May 2024, appointed permanent CFO; compensation unchanged; retains board seat.","Stockholders approved amendment to 2023 Stock Incentive Plan adding 2,000,000 authorized shares for awards.","Press release details strategic shift: AI-driven drug repurposing via Sarborg partnership, animal health collaboration with Manoira, and evaluation of cryptocurrency treasury reserve strategy.","All five director nominees elected: Andrew Regan, Freda Lewis-Hall, James Bligh, Chele Chiavacci Farley, Simon Fry; auditor CBIZ CPAs P.C. ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162386,"accession_number":"0001641172-25-014322","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Conduit enters joint development with Manoira for AZD1656/AZD5658 in animal health","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Conduit grants Manoira non-exclusive license to AZD1656 and AZD5658 for veterinary use; Manoira funds development.","Conduit issued 154,799 shares at $3.23/share (~$500K) to Manoira, a company controlled by CEO Andrew Regan.","Initial evaluation focuses on AZD1656 in canine osteoarthritis; plans combination with patented CBDA co-crystal.","Conduit retains all human IP and data ownership; agreement provides cross-species translational data for human programs.","Collaboration targets potential revenue in $15B animal health market (6.5% CAGR through 2027)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162385,"accession_number":"0001641172-25-013468","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Conduit Pharmaceuticals sets 2025 annual meeting for Aug 5; proxy deadlines June 17","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for August 5, 2025; record date is July 3, 2025.","Stockholder proposals for proxy inclusion must be received by June 17, 2025.","Director nominations and other business proposals also due by June 17, 2025 per bylaws.","Meeting date is more than 30 days before anniversary of 2024 meeting, triggering this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162384,"accession_number":"0001641172-25-011183","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Conduit Pharmaceuticals announces 1-for-15 reverse stock split effective May 19, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-15 reverse split effective May 19, 2025 at 5:00 p.m. ET; split-adjusted trading begins May 20 under ticker CDT.","Post-split outstanding shares reduced to approximately 755,900 from roughly 11.3 million pre-split.","No fractional shares issued; cash payment in lieu at closing price on May 19.","Par value unchanged at $0.0001; new CUSIP number 20678X 304; warrants and equity awards proportionally adjusted.","Stockholders approved reverse split at special meeting on May 5, 2025; board set exact ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162383,"accession_number":"0001641172-25-008854","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Conduit Pharma stockholders approve reverse stock split up to 1-for-250 at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal passed with 5,065,868 votes for, 496,473 against, 1,438 abstentions.","Board may implement split at ratios from 1-for-2 to 1-for-100, aggregate not exceeding 1-for-250.","The reverse stock split amendments to the certificate of incorporation have been authorized.","Company's common stock trades under CDT on Nasdaq; warrants trade under CDTTW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162382,"accession_number":"0001641172-25-006224","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Conduit Pharmaceuticals changes auditor from Marcum to CBIZ CPAs; going concern and material weaknesses cited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 24, 2025; CBIZ CPAs P.C. appointed on April 25, 2025.","Audit reports for FYE 2024 and 2023 included a going concern explanatory paragraph due to substantial doubt.","Material weaknesses in internal controls identified: inadequate segregation of duties, lack of review controls, restatement.","No accounting disagreements between Company and Marcum; no reportable events except the material weaknesses noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162381,"accession_number":"0001641172-25-005036","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Conduit Pharma appoints founder Andrew Regan as CEO; Tapolczay transitions to licensing role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Tapolczay resigned as CEO and board member effective April 12, 2025; to serve as Head of Licensing & Strategy at £240K salary.","Andrew Regan appointed CEO effective April 15, 2025; continues as director and waives compensation except expense reimbursement.","Faith Charles resigned from board effective April 16, 2025 for personal reasons; board reduced from seven to five members.","Tapolczay to focus on out-licensing tapinarof patents; Regan highlights AI collaboration with Sarborg and 20-year patent strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162380,"accession_number":"0001641172-25-002774","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Conduit Pharmaceuticals enters AI analytics deal for AstraZeneca assets; issues 2.26M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered additional agreement with Sarborg for AI analysis of AZD1656, AZD5658, AZD5904 clinical data to identify repurposing opportunities.","Agreement term six months, total consideration $2.0M (cash or stock at company's election).","Issued 1,853,933 shares to satisfy ~$1.65M of fees; also issued 410,113 shares for consulting services.","Company had 9,549,800 shares outstanding as of March 31, 2025.","Aim is to re-evaluate failed endpoints from AstraZeneca trials to identify benefited patient subgroups."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162378,"accession_number":"0001641172-25-002400","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K/A","filed_at":"2025-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Conduit Pharmaceuticals regains full Nasdaq compliance after $8.3M raise and debt conversion","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted pro-forma financials showing stockholder's equity of $2.8M vs $2.5M minimum required.","Raised $8.332M from at-the-market offering; converted $1.785M debt into 924,200 shares.","Compliant with Market Value of Publicly Held Securities standard (>$1M) as of March 7, 2025.","Nasdaq Capital Market Equity Standard compliance achieved as of March 31, 2025 and continuing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162379,"accession_number":"0001641172-25-002147","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Conduit Pharmaceuticals provides Nasdaq compliance update; equity above $2.5M threshold","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Submitted pro-forma financials showing Stockholder's Equity of $2.8M as of March 31, 2025, above Nasdaq's $2.5M minimum.","Currently compliant with Market Value of Publicly Held Securities standard (>$1.0M).","Application to transfer to Nasdaq Capital Market was made on March 7, 2025.","CEO David Tapolczay signed the report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180398,"accession_number":"0001493152-25-009330","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Conduit Pharmaceuticals receives Nasdaq extension, plans transfer to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearing Panel granted extension to March 31, 2025 to regain MVPHS and MVLS compliance.","Company must file application to transfer to Nasdaq Capital Market by March 12, 2025.","Bid Price compliance regained as of February 26, 2025; extension conditional on meeting all listing rules.","Company believes it can satisfy equity standard of >$2.5M stockholder's equity before deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180397,"accession_number":"0001493152-25-007573","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["1.02","8.01","3.01"],"status":"ready","headline":"Conduit Pharmaceuticals repays $926k note, receives Nasdaq delisting basis for continued listing deficiencies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid remaining $926,149 on Senior Note to Nirland Limited on Feb 13, 2025; all assets now free of liens.","On Feb 12, 2025, Nasdaq notified Conduit it did not regain compliance with MVPHS and MVLS requirements; added as delisting bases.","Company presented compliance plan to Nasdaq Hearing Panel on Feb 11; awaiting determination; no assurance of continued listing.","Original Senior Note was $2,650,000 ($500k OID); full satisfaction removes all security interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180396,"accession_number":"0001493152-25-005796","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Conduit Pharmaceuticals repays $600K note; lender converts $1.7M Senior Note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid full principal of $600,000 promissory note on Feb 7, 2025; note bore 12% interest and matured Oct 31, 2025.","Nirland Limited converted ~$1.7M of $2.65M Senior Note principal into common shares as of Feb 10, 2025.","Senior Note issued Aug 6, 2024 with 12% interest and $500,000 original issuance discount.","Both transactions reduce Conduit's outstanding debt obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180395,"accession_number":"0001493152-25-003316","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Conduit Pharmaceuticals announces 1-for-100 reverse stock split to meet Nasdaq bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Jan 24, 2025 at 5pm ET; shares begin trading on split-adjusted basis Jan 27 under ticker CDT.","Every 100 shares combined into 1; no fractional shares; cash in lieu for fractional interests.","Post-split outstanding shares reduced to approximately 1.5 million.","Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180394,"accession_number":"0001493152-25-002176","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Conduit shareholders approve issuance of up to 135.9M shares via warrant exercises and note conversions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 1: approved 2,862,596 shares from warrant exercise (38.1M for, 1.5M against).","Proposal 2: approved up to 75M shares from Nirland Limited note conversion (35.0M for, 4.6M against).","Proposal 3: approved up to 58M shares from A.G.P./Alliance Global Partners note conversion (35.0M for, 4.6M against).","All proposals passed with >35M votes for each; no broker non-votes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197221,"accession_number":"0001493152-24-051089","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["3.01","5.02","5.07"],"status":"ready","headline":"Nasdaq notifies Conduit of delisting due to low price; shareholders approve reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price ≤ $0.10 for 10 consecutive days; delisting set for Dec 27 unless hearing requested.","Company intends to request a hearing before Nasdaq Hearings Panel; delisting stayed pending decision.","Stockholders approved a reverse stock split at ratio between 1-for-10 and 1-for-100 at Dec 18 annual meeting.","Simon Fry appointed director and Audit Committee member; granted option for 420,000 shares on Dec 18.","Nasdaq confirmed compliance with audit committee requirements after Fry's appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197220,"accession_number":"0001493152-24-050443","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Conduit signs AI services deal with Sarborg; upfront $400K, up to $1.8M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with SARBORG for algorithmic AI/cybernetics services to optimize drug development, repurposing, and clinical trials.","Initial consideration: $200,000 cash + $200,000 via 2,272,727 shares (based on closing price on Dec 11).","Milestone payments up to $1.8M payable in cash or shares at Conduit's discretion.","Board member Dr. Andrew Regan serves on both boards (related party transaction).","Services span three phases: initial (0-24 weeks), development (24-36 weeks), ongoing (36-52 weeks)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197219,"accession_number":"0001493152-24-047631","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Conduit Pharma issues $5.74M convertible note to A.G.P. and amends Nirland note; conversion needs stockholder approval","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $5,737,500 convertible note to A.G.P. for deferred commission; 5.5% interest, matures Nov 25, 2025.","Second Amendment to $2.65M Nirland note restricts conversion until stockholder approval; $100K/day penalty if meeting not held by Jan 9, 2025.","Conversion price $0.10/share (adjusted for reverse splits); up to 75M shares (Nirland) and 58M shares (A.G.P.) issuable upon conversion.","Both notes require stockholder approval under Nasdaq rules before conversion can occur.","Company can prepay notes; customary default provisions included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197218,"accession_number":"0001493152-24-046849","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Conduit Pharma appoints director Fry (420K options); amends CFO pay (£400K, 40% bonus) and quorum rule","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Fry appointed as director effective Dec 18, 2024; receives initial option for 420,000 common shares.","CFO James Bligh's employment amendment: £400K base salary, discretionary bonus up to 40%, 6-month notice.","Bylaws amended: quorum reduced from majority to one-third voting power, effective after 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197217,"accession_number":"0001493152-24-046068","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Conduit Pharmaceuticals restates Q1 and Q2 2024 financials; reclassifies deferred commission to current liability","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Previously issued unaudited financials for Q1 and Q2 2024 should no longer be relied upon due to reclassification error.","Restatement reclassifies deferred commission payable from long-term to current liability; no impact on total liabilities.","Company will file amendments to its Q1 and Q2 2024 Forms 10-Q to correct the balance sheet classification.","Discussions with auditor Marcum LLP and Audit Committee led to the non-reliance determination on November 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197216,"accession_number":"0001493152-24-043330","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Conduit Pharmaceuticals secures $1.2M in new loans; issues warrants and amends existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Bridge Loan with A.G.P. for up to $600k at 4.21% due Dec 31, 2024; issued warrants for 2.86M shares at $0.1048 per share, subject to shareholder approval.","Issued $600k promissory note to Nirland Limited at 12% per annum, maturing Oct 31, 2025; includes 1% arrangement fee.","Amended prior $2.65M Nirland note to allow conversion to common stock and removed mandatory prepayment and right of first refusal.","Proceeds from ATM offering of up to ~$3.5M will be used first to repay the A.G.P. Bridge Note.","Warrants and conversion shares are unregistered, issued under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197215,"accession_number":"0001493152-24-041154","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Conduit extends $800K convertible note, issues 2.78M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Original $800K convertible note (20% interest) due Sept 20, 2024 amended; maturity extended to Oct 20, 2024, with possible further 30-day extensions.","On Oct 11, 2024, issued 2,781,250 shares of common stock: $80K worth at market price plus 2,000,000 shares.","Payees waived all previously due interest and principal payments; all now due on new Repayment Date.","Company may further extend maturity to Nov 19 or Dec 19, 2024 at its discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213482,"accession_number":"0001493152-24-035334","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Conduit Pharmaceuticals postpones 2024 Annual Meeting to Dec 18, sets deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting postponed from Oct 2 to Dec 18, 2024.","Record date for meeting set to Oct 25, 2024.","​Due to no 2023 meeting, deadline for Rule 14a-8 proposals is Sept 16, 2024.","Board cited best interests of stockholders for the postponement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213481,"accession_number":"0001493152-24-032854","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Conduit Pharmaceuticals receives Nasdaq delisting notices; discloses 31% of shares pledged without company knowledge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Conduit on Aug 15, 2024 for non-compliance: MVPHS <$15M and MVLS <$50M; 180-day cure period until Feb 11, 2025.","Company disclosed that a director's subsidiary pledged a substantial amount of shares without company knowledge.","Approximately 30M shares (31% of outstanding) are subject to a third-party pledge with a significant stockholder.","Board formed a Special Committee to review pledge transactions and a Trading Review Committee to investigate trading patterns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213480,"accession_number":"0001493152-24-030681","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Conduit licenses three AstraZeneca assets for autoimmune and infertility; issues 9.5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license from AstraZeneca for HK-4 glucokinase activators AZD1656, AZD5658 and MPO inhibitor AZD5904.","Conduit pays $1.5M upfront and issues 9.5M shares to AstraZeneca; AstraZeneca gets sublicense revenue share.","AstraZeneca receives right of first negotiation if Conduit seeks third-party rights to licensed compounds.","Conduit plans to initiate Phase II trials in autoimmune disorders and idiopathic male infertility in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213479,"accession_number":"0001493152-24-030568","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Conduit Pharmaceuticals issues $2.65M secured note at 12%, 12.5M shares to Nirland","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Senior Secured Promissory Note of $2,650,000 (incl. $500,000 OID), 12% interest, matures Aug 5, 2025.","$1,675,000 funded at close; $475,000 due after resale registration declared effective.","Issued 12,500,000 shares of common stock as Closing Common Stock.","Note secured by all assets; personally guaranteed by board member Dr. Andrew Regan.","Nirland gets right of first refusal to participate in future equity or debt offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213477,"accession_number":"0001493152-24-026957","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K/A","filed_at":"2024-07-11T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Conduit Pharmaceuticals announces Oct 2, 2024 annual meeting; record date Aug 12, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting set for October 2, 2024; record date for stockholders is August 12, 2024.","Deadline for Rule 14a-8 stockholder proposals and director nominations is July 11, 2024.","Amendment corrects prior 8-K; no other changes to previously disclosed information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213478,"accession_number":"0001493152-24-025805","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Conduit Pharmaceuticals sets 2024 annual meeting for Oct 2; deadline for shareholder proposals July 11","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting date: October 2, 2024; record date: August 20, 2024.","Deadline for Rule 14a-8 shareholder proposals for inclusion in proxy is July 11, 2024.","Company did not hold an annual meeting in 2023, triggering special deadline notice.","Proposals must comply with SEC Rule 14a-8 and company bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232662,"accession_number":"0001493152-24-022228","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Conduit Pharma gets Nasdaq deficiency notice after audit committee director resigns","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Conduit on May 28, 2024 that audit committee now has only two independent directors.","Non-compliance triggered by resignation of director Jennifer McNealey from Board and committees.","Cure period runs until earlier of next annual meeting or May 13, 2025; no immediate delisting.","Company intends to regain compliance by adding a third independent audit committee member.","Common stock (CDT) and warrants (CDTTW) continue trading on Nasdaq during cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}